Development of HIV-1 fusion inhibitors targeting gp41.

Abstract

The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41. In this review, the development of HIV-1 fusion inhibitors targeting gp41 including peptide inhibitors, small molecule inhibitors, vaccines and neutralized antibodies will be discussed.

• Authors: K Lu, M R Asyifah, F Shao, D Zhang
• Journal: Current medicinal chemistry (Curr Med Chem) Vol. 21 Issue 17 Pg. 1976-96 (Jun 2014) ISSN: 1875-533X [Electronic] United Arab Emirates
• PMID: 24350848 (Publication Type: Journal Article, Review)

Chemical References

• HIV Envelope Protein gp41
• HIV Fusion Inhibitors
• Peptides
• Small Molecule Libraries

Topics

• Amino Acid Sequence
• Drug Design
• HIV Envelope Protein gp41 (antagonists & inhibitors, chemistry, metabolism)
• HIV Fusion Inhibitors (chemistry, pharmacology)
• HIV Infections (drug therapy, metabolism, virology)
• HIV-1 (drug effects, physiology)
• Host-Pathogen Interactions (drug effects)
• Humans
• Membrane Fusion (drug effects)
• Molecular Sequence Data
• Peptides (chemistry, pharmacology)
• Small Molecule Libraries (chemistry, pharmacology)